Epilepsy Pipeline Tracker

 
The mission of the Epilepsy Foundation includes accelerating new therapies for people living with epilepsy and seizures. As a reflection of our commitment and as a service to the community we are pleased to provide here the pipeline of epilepsy therapies in various stages of development. We thank all of the individuals and organizations whose efforts are reflected in these seeds of hope. The Epilepsy Foundation makes no claims of accuracy of the following data. Although every effort is made to continuously update this list, some errors are inevitable. Companies or academicians or others who are directly involved with any of the therapies listed here are strongly encouraged to keep us updated by contacting contactus@efa.org of any needed changes.
NEW DRUGS IN DEVELOPMENT edit

AMO-01

  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators Icahn School of Medicine at Mount Sinai
Mechanism of Action |Other : inhibitor of the Ras-ERK pathway.
View Details
NEW DRUGS IN DEVELOPMENT edit

AMP-X-0079

  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators AurimMed Pharma, Inc., Epilepsy Foundation (EF)
Mechanism of Action : N/A
View Details
NEW DRUGS IN DEVELOPMENT edit

Anavex 2-73 / Blarcamesine

  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators Anavex Life Science Corp/ International Rett Syndrome Foundation
Mechanism of Action |Sigma-1 : modulates sigma-1 receptor
View Details
NEW DRUGS IN DEVELOPMENT edit

Anti-Seizure and Anti-Epileptogenic Effects of New, Selective mTor Inhibitors

  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators PIQUR Therapeutics, Wolfgang Loescher, Epilepsy Foundation (EF)
Mechanism of Action |mTOr : mTOR inhibitors
View Details
XLSX

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline
P